KR102002103B1 - 인간 엔테로바이러스에 대한 백신 - Google Patents

인간 엔테로바이러스에 대한 백신 Download PDF

Info

Publication number
KR102002103B1
KR102002103B1 KR1020187026574A KR20187026574A KR102002103B1 KR 102002103 B1 KR102002103 B1 KR 102002103B1 KR 1020187026574 A KR1020187026574 A KR 1020187026574A KR 20187026574 A KR20187026574 A KR 20187026574A KR 102002103 B1 KR102002103 B1 KR 102002103B1
Authority
KR
South Korea
Prior art keywords
enterovirus
protein
hev71
cells
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187026574A
Other languages
English (en)
Korean (ko)
Other versions
KR20180104201A (ko
Inventor
매리 제인 카르도사
모하마드 파크루딘 자미루딘
샤리파 빈티 하미드
Original Assignee
센티넥스트 테라퓨틱스 에쓰디엔 비에이취디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센티넥스트 테라퓨틱스 에쓰디엔 비에이취디 filed Critical 센티넥스트 테라퓨틱스 에쓰디엔 비에이취디
Publication of KR20180104201A publication Critical patent/KR20180104201A/ko
Application granted granted Critical
Publication of KR102002103B1 publication Critical patent/KR102002103B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14041Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32323Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32351Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32371Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187026574A 2011-11-03 2012-11-01 인간 엔테로바이러스에 대한 백신 Expired - Fee Related KR102002103B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MYPI2011005318 2011-11-03
MYPI2011005318 2011-11-03
PCT/IB2012/003114 WO2013098655A2 (en) 2011-11-03 2012-11-01 Antigens and vaccines directed against human enteroviruses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026513A Division KR101900460B1 (ko) 2011-11-03 2012-11-01 인간 엔테로바이러스에 대한 백신

Publications (2)

Publication Number Publication Date
KR20180104201A KR20180104201A (ko) 2018-09-19
KR102002103B1 true KR102002103B1 (ko) 2019-07-19

Family

ID=47215776

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187026574A Expired - Fee Related KR102002103B1 (ko) 2011-11-03 2012-11-01 인간 엔테로바이러스에 대한 백신
KR1020177026513A Expired - Fee Related KR101900460B1 (ko) 2011-11-03 2012-11-01 인간 엔테로바이러스에 대한 백신
KR1020147015175A Expired - Fee Related KR101782451B1 (ko) 2011-11-03 2012-11-01 인간 엔테로바이러스에 대한 백신

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177026513A Expired - Fee Related KR101900460B1 (ko) 2011-11-03 2012-11-01 인간 엔테로바이러스에 대한 백신
KR1020147015175A Expired - Fee Related KR101782451B1 (ko) 2011-11-03 2012-11-01 인간 엔테로바이러스에 대한 백신

Country Status (16)

Country Link
US (3) US9987350B2 (enExample)
EP (2) EP2773372B1 (enExample)
JP (2) JP6190378B2 (enExample)
KR (3) KR102002103B1 (enExample)
CN (2) CN104093420B (enExample)
AU (1) AU2012360168C1 (enExample)
BR (1) BR112014010658A2 (enExample)
CA (1) CA2854594C (enExample)
CL (1) CL2014001160A1 (enExample)
HK (2) HK1245128A1 (enExample)
MX (2) MX363409B (enExample)
MY (1) MY172501A (enExample)
PH (2) PH12014501041B1 (enExample)
SG (1) SG11201401998VA (enExample)
TW (2) TWI571512B (enExample)
WO (1) WO2013098655A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700295B (zh) 2013-12-16 2020-08-01 馬來西亞商Mab探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
TWI686475B (zh) * 2014-04-29 2020-03-01 財團法人國家衛生研究院 對抗腸病毒感染之基於腺病毒載體之疫苗
CN111925423B (zh) * 2014-11-07 2022-08-19 普莱柯生物工程股份有限公司 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用
CN106554965B (zh) * 2015-09-28 2019-08-27 斯澳生物科技(苏州)有限公司 用于制备ev71病毒样颗粒的核酸构建体和方法
CN105348391B (zh) * 2015-11-03 2019-06-28 李越希 埃可病毒6型vp1蛋白特异性抗原表位及其融合蛋白的制备、应用
CN105802923B (zh) * 2016-04-14 2019-07-16 中国科学院生物物理研究所 一种重组脊髓灰质炎病毒样颗粒及其制备方法与应用
SG10202010435XA (en) * 2016-04-22 2020-11-27 Integrated Research Associates Llc Improved method for producing virus like particles
US20190224304A1 (en) * 2016-10-07 2019-07-25 Sentinext Therapeutics Sdn Bhd Chimeric enterovirus virus-like particles
US20190247488A1 (en) 2016-10-07 2019-08-15 Sentinext Therapeutics Sdn Bhd Expression cassettes and methods for obtaining enterovirus virus-like particles
KR102091372B1 (ko) 2017-02-28 2020-05-27 대한민국 엔테로바이러스 71형 불활화 백신 및 이의 용도
CN108624601B (zh) * 2017-03-17 2023-08-11 中国科学院上海巴斯德研究所 酵母表达的柯萨奇病毒a10病毒样颗粒及其应用
SG11201913826QA (en) * 2017-07-03 2020-01-30 Bharat Biotech Int Ltd A synthetic polypeptide epitope based vaccine composition
CN108152511B (zh) * 2017-12-20 2019-01-04 广州瑞辉生物科技股份有限公司 柯萨奇A16病毒抗原多肽及其IgM抗体检测试剂盒
CN108424881B (zh) * 2018-03-23 2021-07-27 中国食品药品检定研究院 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用
WO2020067027A1 (ja) * 2018-09-28 2020-04-02 一般財団法人阪大微生物病研究会 Vlp発現cho細胞株の構築
CN110045105B (zh) * 2018-11-09 2022-04-26 广州市妇女儿童医疗中心 柯萨奇A16病毒IgA抗体量子点免疫荧光层析试纸条及试剂盒
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
CN110684781B (zh) * 2019-06-24 2021-05-28 四川农业大学 一种3型鸭甲肝病毒突变基因isa-a117c-t1142a及构建方法
CN112048004B (zh) * 2020-07-14 2021-10-22 桂林医学院 一种柯萨奇病毒b5型病毒样颗粒、其制备方法及应用
WO2022070210A1 (en) * 2020-09-29 2022-04-07 Bharat Biotech International Limited Stable formulations of low abundance enteroviruses vaccines and process of manufacture thereof
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法
CN115010813B (zh) * 2022-05-19 2024-04-05 桂林医学院 一种肠道病毒71型病毒样颗粒、其制备方法及应用
CN116200348A (zh) * 2022-09-21 2023-06-02 武汉生物制品研究所有限责任公司 一种适应Vero细胞的柯萨奇病毒A10型毒株的构建方法及其应用
US11826418B1 (en) 2023-01-06 2023-11-28 King Faisal University Virus-like particle (VLP)-based vaccine against CVB4
WO2025029700A1 (en) * 2023-07-28 2025-02-06 Modernatx, Inc. Vlp enteroviral vaccines
CN117456519B (zh) * 2023-12-22 2024-03-12 江西科益高新技术有限公司 一种用于工控安全的仿真光电靶标装置及其仿真方法
CN120665160A (zh) * 2025-08-21 2025-09-19 国药中生生物技术研究院有限公司 肠道病毒71型的突变体及其病毒样颗粒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8102740A (nl) 1981-06-05 1983-01-03 Nederlanden Staat Virusvaccins en werkwijze ter bereiding daarvan.
WO2003046138A2 (en) * 2001-11-26 2003-06-05 Duke University Genetically stable expression vector
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
EP1479761A1 (en) * 2003-05-21 2004-11-24 PrimaGen Holding B.V. New enterovirus, vaccines, medicaments and diagnostic kits
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN101365480B (zh) * 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
WO2008005777A2 (en) * 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
RU2528858C2 (ru) * 2008-08-28 2014-09-20 Новартис Аг Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
CN101831410B (zh) 2009-03-09 2013-04-17 北京工业大学 重组肠病毒71型病毒样颗粒的制备方法
GB0918375D0 (en) * 2009-10-20 2009-12-02 Animal Health Inst Construct
WO2012108840A1 (en) * 2011-02-08 2012-08-16 Temasek Life Sciences Laboratory Limited A novel expression cassette for efficient surface display of antigenic proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
International Journal of Infectious Diseases. Vol. 12, No. Suppl. 1, E254, abstract No. 43.009 (2008)
Journal of General Viology. Vol. 70, No. 6, pp. 1453-1463 (1989) 1부.*
Journal of Virology. Vol. 65, No. 4, pp. 2088-2092 (1991)
Vaccine. Vol. 26, No. 15, pp. 1855-1862 (2008)
Virology. Vol. 192, No. 2, pp. 512-524 (1993)
World Journal of Gastroenterology. Vol. 12, No. 6, pp. 921-927 (2006)

Also Published As

Publication number Publication date
PH12019500289A1 (en) 2020-02-17
KR101900460B1 (ko) 2018-11-08
EP3290050A1 (en) 2018-03-07
EP2773372A2 (en) 2014-09-10
TW201333195A (zh) 2013-08-16
CA2854594A1 (en) 2013-07-04
CN107441484A (zh) 2017-12-08
HK1251492B (en) 2019-10-25
MY172501A (en) 2019-11-27
BR112014010658A2 (pt) 2017-06-13
JP6419271B2 (ja) 2018-11-07
MX363409B (es) 2019-03-20
CN104093420B (zh) 2017-07-28
PH12014501041A1 (en) 2014-08-04
US9987350B2 (en) 2018-06-05
US20180271971A1 (en) 2018-09-27
TW201716576A (zh) 2017-05-16
AU2012360168A2 (en) 2015-04-30
JP6190378B2 (ja) 2017-08-30
WO2013098655A9 (en) 2013-12-19
TWI626308B (zh) 2018-06-11
US10555997B2 (en) 2020-02-11
JP2014532691A (ja) 2014-12-08
US20150140027A1 (en) 2015-05-21
AU2012360168A1 (en) 2014-05-22
HK1202803A1 (en) 2015-10-09
EP3290050B1 (en) 2019-01-02
KR20180104201A (ko) 2018-09-19
CA2854594C (en) 2018-08-21
PH12014501041B1 (en) 2014-08-04
TWI571512B (zh) 2017-02-21
US10548964B2 (en) 2020-02-04
KR20170109700A (ko) 2017-09-29
AU2012360168B2 (en) 2017-06-22
WO2013098655A3 (en) 2013-09-12
KR20140096343A (ko) 2014-08-05
MX2014005315A (es) 2015-03-09
EP2773372B1 (en) 2018-12-26
AU2012360168C1 (en) 2017-09-28
JP2017226677A (ja) 2017-12-28
MX2018013782A (es) 2021-12-08
KR101782451B1 (ko) 2017-09-29
CN104093420A (zh) 2014-10-08
WO2013098655A2 (en) 2013-07-04
US20180243400A1 (en) 2018-08-30
SG11201401998VA (en) 2014-05-29
HK1245128A1 (zh) 2018-08-24
CL2014001160A1 (es) 2014-11-03

Similar Documents

Publication Publication Date Title
KR102002103B1 (ko) 인간 엔테로바이러스에 대한 백신
HK1251492A1 (en) Vaccines directed against human enteroviruses
US20150056244A1 (en) Antigens and Vaccines Directed Against Human Enteroviruses
US20070275015A9 (en) West nile virus vaccine
US20190247488A1 (en) Expression cassettes and methods for obtaining enterovirus virus-like particles
WO2018066999A2 (en) Chimeric enterovirus virus-like particles
CN111961654B (zh) 耐热表型稳定遗传、携带负标记的重组口蹄疫病毒无毒株及o/a型口蹄疫二价灭活疫苗
RU2215035C2 (ru) Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты)
HK1202803B (en) Antigens and vaccines directed against human enteroviruses
TW200844227A (en) Recombinant viral proteins and particles
JPH07502403A (ja) 人工タンパク質分解切断部位を含む組み換えウィルス
TW201825675A (zh) 用於獲得腸病毒病毒樣顆粒之表現匣及方法
TW201825676A (zh) 嵌合型腸病毒病毒樣顆粒

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

Not in force date: 20220716

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220716

St.27 status event code: N-4-6-H10-H13-oth-PC1903